cannabis
Australian firm Althea enters UK medicinal cannabis market
February 13, 2019Research and Development Epidiolex, GW Pharma, Medical marijuana, NHS, UK, cannabis
Melbourne-based medicinal cannabis company Althea has become one of the first companies to enter the UK market after the British …
Novartis inks deal with Canadian cannabis firm Tilray
December 18, 2018Research and Development Marijuana, Novartis, Sandoz, Tilray, cannabis
Shares in Canadian cannabis company Tilray jumped by more than 11% today after the British Columbia-based firm announced its entry …
GW Pharma’s Epidiolex becomes first cannabis-based medicine to be made available in United States
November 2, 2018Medical Communications Epidiolex, GW Pharma, Medical marijuana, cannabidiol, cannabis
GW Pharma’s Epidiolex has become the first plant-derived, cannabis-based medicine to be made available on prescription in all 50 US …
Medical Marijuana to be legalised in Thailand and Malaysia as drug becomes available on prescription in UK
November 1, 2018Business Services, Medical Communications Medical marijuana, UK, cannabis, malaysia, thailand
Thailand’s public health ministry is working to make medical marijuana legal by next month. The shift is expected to come …
Cannabis-derived medicinal products to become available in UK
July 26, 2018Medical Communications cannabis, law, medicinal marijuana, prescription, sajid javid, schedule drugs, uk politics
Home Secretary Sajid Javid has announced that cannabis derived medicinal products will be made available on prescription “by the autumn” …
European cannabis market set to be worth €115.7 billion by 2028
July 16, 2018Sales and Marketing Europe, Legislation, cannabis, medicinal marijuana
The European cannabis market is set to be worth €115.7 billion by 2028, according to a report released by the …
Zynerba’s cannabis-based transdermal patch fails at Phase 1, shares slide 21%
July 6, 2018Medical Communications, Research and Development GW Pharma, Zynerba, cannabidinol, cannabinol, cannabis, pharma, trial failure
As public focus on the issue of medicinal cannabis continues to grow, Zynerba Pharmaceuticals has announced that its transdermal tetrahydrocannabinol …
Review signals step towards legalisation of medicinal cannabis in UK
July 4, 2018Research and Development England, cannabis, pharma, review, thc
England’s Chief Medical Officer Dame Sally Davies has concluded that there is “conclusive evidence” that cannabis is medically beneficial for …
GW Pharma’s Epidiolex becomes first cannabis-based medicine available in US
June 26, 2018Manufacturing and Production, Sales and Marketing FDA, GW Pharma, Lennox-Gastaut syndrome, UK, US, cannabidiol, cannabis
In what could prove to be a pivotal decision, UK biotech GW Pharmaceuticals has announced that its oral cannabidiol solution …
Top Ten most popular articles on Pharmafile.com this week
March 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Canada, Celgene, Lundbeck, Marijuana, Novartis, Roche, Vertex, brexit, cannabis, multiple sclerosis, neuroscience, pharma
As me move startlingly quickly towards Easter, it’s time for another Top Ten rundown. This week, Celgene surprised the industry …
FDA issues warnings in crackdown on baseless cannabis miracle cures
November 2, 2017Research and Development, Sales and Marketing FDA, cannabidiol, cannabis, pharma
The FDA has issued a warning over cannabis-based therapies which promise the ability to cure cancer, asserting that such treatments …
GW Pharma releases positive data on cannabidiol-based Phase III trial
September 28, 2016Research and Development Epidiolex, GW Pharmaceuticals, Marijuana, Medical marijuana, cannabis
GW Pharmaceuticals’ Epidiolex is designed to treat seizures in a rare form of epilepsy called Lennox-Gaustaut Syndrome. GW pharmaceuticals published …
GW Pharma’s cannabis-based epilepsy drug granted orphan designation by FDA
April 21, 2016Research and Development, Sales and Marketing GW Pharma, cannabis, cannabis-based, epilepsy
GW Pharmaceuticals (NASDAQ: GWPH) has announced that the US Food and Drug Administration has granted its cannabis-based epilepsy drug, Epidiolex …
